CAR T Cells in Lymphoma and Multiple Myeloma

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".

Deadline for manuscript submissions: 31 January 2025 | Viewed by 681

Special Issue Editors


E-Mail Website
Guest Editor
Division of Hematology, Medical Oncology, Mayo Clinic, Phoenix, AZ 85054, USA
Interests: lymphoma; cellular therapies; CAR T cells

E-Mail Website
Guest Editor
Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ 85054, USA
Interests: multiple myeloma; cellular therapies; dysproteinemia

Special Issue Information

Dear Colleagues,

Cellular therapies, including chimeric antigen receptor (CAR) T cell therapy and bispecific antibodies (BiTE), have changed the treatment landscape for lymphomas and multiple myeloma. These treatments are primarily used in the relapsed or refractory setting, although exploration in early lines of therapy is under investigation in clinical trials. Despite exciting outcomes, there are a number of challenges that remain. Examples include poor T cell expansion and short-term T cell persistence, leading to suboptimal response and/or relapse. The purpose of this Special Issue is to understand how to decrease the toxicity and increase the efficacy of CAR T cell therapy in patients with lymphoma or multiple myeloma.

Dr. Javier Munoz
Dr. Julia Erin Wiedmeier-Nutor
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • multiple myeloma
  • lymphoma
  • CAR T therapy
  • bi-specific antibodies
  • cellular therapy

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

19 pages, 303 KiB  
Review
Circulating Tumor DNA as a Complementary Prognostic Biomarker during CAR-T Therapy in B-Cell Non-Hodgkin Lymphomas
by Sarah Monick and Allison Rosenthal
Cancers 2024, 16(10), 1881; https://doi.org/10.3390/cancers16101881 - 15 May 2024
Viewed by 427
Abstract
The emergence of CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment paradigm for R/R B-cell NHLs. However, challenges persist in accurately evaluating treatment response and detecting early relapse, necessitating the exploration of novel biomarkers. Circulating tumor DNA (ctDNA) via liquid [...] Read more.
The emergence of CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment paradigm for R/R B-cell NHLs. However, challenges persist in accurately evaluating treatment response and detecting early relapse, necessitating the exploration of novel biomarkers. Circulating tumor DNA (ctDNA) via liquid biopsy is a non-invasive tool for monitoring therapy efficacy and predicting treatment outcomes in B-NHL following CAR-T therapy. By overcoming the limitations of conventional imaging modalities, ctDNA assessments offer valuable insights into response dynamics, molecular mechanisms of resistance, and early detection of molecular relapse. Integration of ctDNA monitoring into clinical practice holds promise for personalized therapeutic strategies, guiding the development of novel targeted therapies, and enhancing patient outcomes. However, standardization of assay methodologies and consensus on clinical response metrics are imperative to unlock the full potential of ctDNA in the management of B-NHL. Prospective validation of ctDNA in clinical trials is necessary to establish its role as a complementary decision aid. Full article
(This article belongs to the Special Issue CAR T Cells in Lymphoma and Multiple Myeloma)
Back to TopTop